CNSP Insider Trading
Insider Ownership Percentage: 0.01%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
CNS Pharmaceuticals Share Price & Price History
Current Price: $6.51
Price Change: ▼ Price Decrease of -0.15 (-2.25%)
As of 12/4/2025 05:00 PM ET
CNS Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/22/2023 | Christopher Downs | CFO | Buy | 0 | $38,100.00 | $0.00 | 1 |  |
| 8/16/2023 | John M Climaco | CEO | Buy | 0 | $54,000.00 | $0.00 | 1 | |
| 4/19/2023 | Jerzy Gumulka | Director | Buy | 0 | $51,000.00 | $0.00 | | |
| 4/17/2023 | Christopher Downs | CFO | Buy | 0 | $96,000.00 | $0.00 | | |
| 4/12/2023 | John M Climaco | CEO | Buy | 0 | $20,700.00 | $0.00 | 1 | |
| 4/10/2023 | Jerzy Gumulka | Director | Buy | 0 | $22,200.00 | $0.00 | | |
| 3/27/2023 | Waldemar Priebe | Major Shareholder | Sell | 0 | $32,700.00 | $0.00 | 5 | |
| 3/24/2023 | Waldemar Priebe | Major Shareholder | Sell | 0 | $32,400.00 | $0.00 | 5 | |
| 3/22/2023 | Waldemar Priebe | Major Shareholder | Sell | 0 | $32,400.00 | $0.00 | 6 | |
| 3/20/2023 | Waldemar Priebe | Major Shareholder | Sell | 0 | $32,400.00 | $0.00 | 6 | |
| 3/17/2023 | Waldemar Priebe | Major Shareholder | Sell | 0 | $33,900.00 | $0.00 | 6 | |
| 3/15/2023 | Waldemar Priebe | Major Shareholder | Sell | 0 | $36,600.00 | $0.00 | 7 | |
| 3/13/2023 | Waldemar Priebe | Major Shareholder | Sell | 0 | $39,000.00 | $0.00 | 7 | |
| 3/10/2023 | Waldemar Priebe | Major Shareholder | Sell | 0 | $38,700.00 | $0.00 | 7 | |
CNS Pharmaceuticals Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 8/14/2025 | Armistice Capital LLC | 406,000 | $0.34M | 0.0% | N/A | 90.222% |  |
| 2/18/2025 | Connective Capital Management LLC | 280,055 | $34K | 0.0% | N/A | 0.487% | |
| 2/17/2025 | Citadel Advisors LLC | 321,874 | $39K | 0.0% | N/A | 0.560% | |
| 2/14/2025 | Jane Street Group LLC | 419,737 | $51K | 0.0% | +1,712.3% | 0.730% | |
| 2/14/2025 | Integrated Wealth Concepts LLC | 250,000 | $30K | 0.0% | N/A | 0.435% | |
| 2/13/2025 | XTX Topco Ltd | 294,919 | $36K | 0.0% | N/A | 0.513% | |
| 2/12/2025 | Geode Capital Management LLC | 387,064 | $47K | 0.0% | +90.5% | 0.673% | |
| 2/7/2025 | Wealthfront Advisers LLC | 216,046 | $26K | 0.0% | N/A | 0.376% | |
| 5/20/2024 | Virtu Financial LLC | 94,246 | $34K | 0.0% | +616.6% | 0.795% | |
| 2/13/2024 | Armistice Capital LLC | 122,000 | $0.16M | 0.0% | N/A | 1.965% | |
| 1/17/2024 | Smith Anglin Financial LLC | 50,000 | $64K | 0.0% | N/A | 0.952% | |
| 8/7/2023 | Acadian Asset Management LLC | 22,292 | $49K | 0.0% | N/A | 1.000% | |
| 7/12/2023 | FSM Wealth Advisors LLC | 16,334 | $38K | 0.0% | N/A | 0.732% | |
Data available starting January 2016
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Read More on CNS Pharmaceuticals
Volume
6,700 shs
Average Volume
12,978 shs
Market Capitalization
$4.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.62
